Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapyDhara M MacDermed, Luke L Miller, Terrance D Peabody, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2004
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanFederico Innocenti, Samir D Undevia, Lalitha Iyer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan, Nicholas J Vogelzang, Everett E Vokes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignanciesTara C Gangadhar, Ezra E W Cohen, Kehua Wu, et al.Leukemia & Lymphoma|October 6, 2010
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseasePeter H O'Donnell, Andrew S Artz, Samir D Undevia, et al.Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patientsEzra E W Cohen, Kehua Wu, Christine Hartford, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II study of sorafenib in patients with metastatic or recurrent sarcomasRobert G Maki, David R D'Adamo, Mary L Keohan, et al.The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.Pageof 2